Standard BioTools Inc. (LAB) Stock Competitors & Peer Comparison
See (LAB) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LAB | $0.89 | -2.12% | 346.5M | -6.83 | -$0.13 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $88.18 | -1.64% | 153.5B | 24.69 | $3.57 | +2.79% |
| ISRG | $411.06 | -0.45% | 145.6B | 49.89 | $8.24 | N/A |
| SYK | $312.20 | +2.15% | 119.6B | 36.07 | $8.65 | +1.10% |
| MDT | $80.20 | -0.16% | 102.9B | 21.50 | $3.73 | +3.55% |
| BSX | $46.91 | -0.55% | 69.7B | 19.62 | $2.39 | N/A |
| EW | $85.11 | -0.76% | 49B | 46.00 | $1.85 | N/A |
| DXCM | $75.37 | +0.16% | 29.1B | 32.35 | $2.33 | N/A |
| RMD | $194.78 | +1.24% | 28.2B | 18.78 | $10.37 | +1.24% |
Stock Comparison
LAB vs BSX-PA Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, LAB is priced at $0.89, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, LAB's ROE is -0.21%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, LAB is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BSX-PA's competition here
LAB vs ABT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, ABT has a market cap of 153.5B. Regarding current trading prices, LAB is priced at $0.89, while ABT trades at $88.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas ABT's P/E ratio is 24.69. In terms of profitability, LAB's ROE is -0.21%, compared to ABT's ROE of +0.12%. Regarding short-term risk, LAB is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ABT's competition here
LAB vs ISRG Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, ISRG has a market cap of 145.6B. Regarding current trading prices, LAB is priced at $0.89, while ISRG trades at $411.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas ISRG's P/E ratio is 49.89. In terms of profitability, LAB's ROE is -0.21%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, LAB is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ISRG's competition here
LAB vs SYK Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, SYK has a market cap of 119.6B. Regarding current trading prices, LAB is priced at $0.89, while SYK trades at $312.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas SYK's P/E ratio is 36.07. In terms of profitability, LAB's ROE is -0.21%, compared to SYK's ROE of +0.15%. Regarding short-term risk, LAB is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SYK's competition here
LAB vs MDT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, MDT has a market cap of 102.9B. Regarding current trading prices, LAB is priced at $0.89, while MDT trades at $80.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas MDT's P/E ratio is 21.50. In terms of profitability, LAB's ROE is -0.21%, compared to MDT's ROE of +0.10%. Regarding short-term risk, LAB is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check MDT's competition here
LAB vs BSX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, BSX has a market cap of 69.7B. Regarding current trading prices, LAB is priced at $0.89, while BSX trades at $46.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas BSX's P/E ratio is 19.62. In terms of profitability, LAB's ROE is -0.21%, compared to BSX's ROE of +0.15%. Regarding short-term risk, LAB is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BSX's competition here
LAB vs EW Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, EW has a market cap of 49B. Regarding current trading prices, LAB is priced at $0.89, while EW trades at $85.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas EW's P/E ratio is 46.00. In terms of profitability, LAB's ROE is -0.21%, compared to EW's ROE of +0.11%. Regarding short-term risk, LAB is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check EW's competition here
LAB vs DXCM Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, DXCM has a market cap of 29.1B. Regarding current trading prices, LAB is priced at $0.89, while DXCM trades at $75.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas DXCM's P/E ratio is 32.35. In terms of profitability, LAB's ROE is -0.21%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, LAB is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check DXCM's competition here
LAB vs RMD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, RMD has a market cap of 28.2B. Regarding current trading prices, LAB is priced at $0.89, while RMD trades at $194.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas RMD's P/E ratio is 18.78. In terms of profitability, LAB's ROE is -0.21%, compared to RMD's ROE of +0.24%. Regarding short-term risk, LAB is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check RMD's competition here
LAB vs PHG Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, PHG has a market cap of 25.7B. Regarding current trading prices, LAB is priced at $0.89, while PHG trades at $26.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas PHG's P/E ratio is 23.00. In terms of profitability, LAB's ROE is -0.21%, compared to PHG's ROE of +0.09%. Regarding short-term risk, LAB is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check PHG's competition here
LAB vs STE Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, STE has a market cap of 20.3B. Regarding current trading prices, LAB is priced at $0.89, while STE trades at $207.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas STE's P/E ratio is 26.14. In terms of profitability, LAB's ROE is -0.21%, compared to STE's ROE of +0.11%. Regarding short-term risk, LAB is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check STE's competition here
LAB vs ABMD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, LAB is priced at $0.89, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas ABMD's P/E ratio is 65.36. In terms of profitability, LAB's ROE is -0.21%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, LAB is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ABMD's competition here
LAB vs ZBH Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, ZBH has a market cap of 17.1B. Regarding current trading prices, LAB is priced at $0.89, while ZBH trades at $88.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas ZBH's P/E ratio is 22.95. In terms of profitability, LAB's ROE is -0.21%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, LAB is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ZBH's competition here
LAB vs SNN Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, SNN has a market cap of 13B. Regarding current trading prices, LAB is priced at $0.89, while SNN trades at $30.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas SNN's P/E ratio is 21.38. In terms of profitability, LAB's ROE is -0.21%, compared to SNN's ROE of +0.12%. Regarding short-term risk, LAB is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SNN's competition here
LAB vs SWAV Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, LAB is priced at $0.89, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas SWAV's P/E ratio is 78.76. In terms of profitability, LAB's ROE is -0.21%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, LAB is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SWAV's competition here
LAB vs PEN Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, LAB is priced at $0.89, while PEN trades at $318.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas PEN's P/E ratio is 73.58. In terms of profitability, LAB's ROE is -0.21%, compared to PEN's ROE of +0.12%. Regarding short-term risk, LAB is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check PEN's competition here
LAB vs ALGN Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, ALGN has a market cap of 12.5B. Regarding current trading prices, LAB is priced at $0.89, while ALGN trades at $174.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas ALGN's P/E ratio is 29.38. In terms of profitability, LAB's ROE is -0.21%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, LAB is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ALGN's competition here
LAB vs GMED Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, GMED has a market cap of 10.8B. Regarding current trading prices, LAB is priced at $0.89, while GMED trades at $80.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas GMED's P/E ratio is 18.78. In terms of profitability, LAB's ROE is -0.21%, compared to GMED's ROE of +0.13%. Regarding short-term risk, LAB is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check GMED's competition here
LAB vs PODD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, PODD has a market cap of 10.4B. Regarding current trading prices, LAB is priced at $0.89, while PODD trades at $149.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas PODD's P/E ratio is 34.98. In terms of profitability, LAB's ROE is -0.21%, compared to PODD's ROE of +0.21%. Regarding short-term risk, LAB is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check PODD's competition here
LAB vs MASI Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, LAB is priced at $0.89, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas MASI's P/E ratio is 44.43. In terms of profitability, LAB's ROE is -0.21%, compared to MASI's ROE of +0.09%. Regarding short-term risk, LAB is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check MASI's competition here
LAB vs BIO-B Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, BIO-B has a market cap of 8.3B. Regarding current trading prices, LAB is priced at $0.89, while BIO-B trades at $307.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas BIO-B's P/E ratio is 51.10. In terms of profitability, LAB's ROE is -0.21%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, LAB is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BIO-B's competition here
LAB vs BRKR Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, BRKR has a market cap of 8.3B. Regarding current trading prices, LAB is priced at $0.89, while BRKR trades at $54.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas BRKR's P/E ratio is -225.96. In terms of profitability, LAB's ROE is -0.21%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, LAB is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BRKR's competition here
LAB vs BRKRP Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, BRKRP has a market cap of 8.1B. Regarding current trading prices, LAB is priced at $0.89, while BRKRP trades at $401.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas BRKRP's P/E ratio is N/A. In terms of profitability, LAB's ROE is -0.21%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, LAB is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BRKRP's competition here
LAB vs BIO Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, BIO has a market cap of 7.7B. Regarding current trading prices, LAB is priced at $0.89, while BIO trades at $285.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas BIO's P/E ratio is 47.48. In terms of profitability, LAB's ROE is -0.21%, compared to BIO's ROE of +0.02%. Regarding short-term risk, LAB is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BIO's competition here
LAB vs GKOS Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, GKOS has a market cap of 7.4B. Regarding current trading prices, LAB is priced at $0.89, while GKOS trades at $126.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas GKOS's P/E ratio is -38.55. In terms of profitability, LAB's ROE is -0.21%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, LAB is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check GKOS's competition here
LAB vs NARI Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, LAB is priced at $0.89, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas NARI's P/E ratio is -59.24. In terms of profitability, LAB's ROE is -0.21%, compared to NARI's ROE of -0.00%. Regarding short-term risk, LAB is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check NARI's competition here
LAB vs LIVN Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, LAB is priced at $0.89, while LIVN trades at $79.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas LIVN's P/E ratio is 40.51. In terms of profitability, LAB's ROE is -0.21%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, LAB is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check LIVN's competition here
LAB vs IRTC Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, LAB is priced at $0.89, while IRTC trades at $113.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas IRTC's P/E ratio is -133.71. In terms of profitability, LAB's ROE is -0.21%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, LAB is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check IRTC's competition here
LAB vs AXNX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, LAB is priced at $0.89, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas AXNX's P/E ratio is -709.80. In terms of profitability, LAB's ROE is -0.21%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, LAB is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check AXNX's competition here
LAB vs ITGR Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, LAB is priced at $0.89, while ITGR trades at $90.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas ITGR's P/E ratio is 22.58. In terms of profitability, LAB's ROE is -0.21%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, LAB is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ITGR's competition here
LAB vs TMDX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, LAB is priced at $0.89, while TMDX trades at $72.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas TMDX's P/E ratio is 16.68. In terms of profitability, LAB's ROE is -0.21%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, LAB is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check TMDX's competition here
LAB vs ESTA Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, ESTA has a market cap of 2.4B. Regarding current trading prices, LAB is priced at $0.89, while ESTA trades at $82.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas ESTA's P/E ratio is -55.88. In terms of profitability, LAB's ROE is -0.21%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, LAB is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check ESTA's competition here
LAB vs AXGN Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, LAB is priced at $0.89, while AXGN trades at $43.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas AXGN's P/E ratio is -67.19. In terms of profitability, LAB's ROE is -0.21%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, LAB is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check AXGN's competition here
LAB vs NUVA Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, LAB is priced at $0.89, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas NUVA's P/E ratio is 75.00. In terms of profitability, LAB's ROE is -0.21%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, LAB is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check NUVA's competition here
LAB vs UFPT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, LAB is priced at $0.89, while UFPT trades at $234.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas UFPT's P/E ratio is 26.73. In terms of profitability, LAB's ROE is -0.21%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, LAB is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check UFPT's competition here
LAB vs PRCT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, LAB is priced at $0.89, while PRCT trades at $25.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas PRCT's P/E ratio is -14.05. In terms of profitability, LAB's ROE is -0.21%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, LAB is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check PRCT's competition here
LAB vs BFLY Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, BFLY has a market cap of 1.5B. Regarding current trading prices, LAB is priced at $0.89, while BFLY trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas BFLY's P/E ratio is -18.53. In terms of profitability, LAB's ROE is -0.21%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, LAB is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check BFLY's competition here
LAB vs IART Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, LAB is priced at $0.89, while IART trades at $17.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas IART's P/E ratio is -2.75. In terms of profitability, LAB's ROE is -0.21%, compared to IART's ROE of -0.48%. Regarding short-term risk, LAB is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check IART's competition here
LAB vs AHCO Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, AHCO has a market cap of 1.4B. Regarding current trading prices, LAB is priced at $0.89, while AHCO trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas AHCO's P/E ratio is -17.22. In terms of profitability, LAB's ROE is -0.21%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, LAB is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check AHCO's competition here
LAB vs HSKA Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, LAB is priced at $0.89, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas HSKA's P/E ratio is -62.49. In terms of profitability, LAB's ROE is -0.21%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, LAB is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check HSKA's competition here
LAB vs ATEC Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, ATEC has a market cap of 1.3B. Regarding current trading prices, LAB is priced at $0.89, while ATEC trades at $8.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas ATEC's P/E ratio is -9.98. In terms of profitability, LAB's ROE is -0.21%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, LAB is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ATEC's competition here
LAB vs ENOV Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, ENOV has a market cap of 1.3B. Regarding current trading prices, LAB is priced at $0.89, while ENOV trades at $21.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas ENOV's P/E ratio is -1.10. In terms of profitability, LAB's ROE is -0.21%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, LAB is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check ENOV's competition here
LAB vs INSP Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, LAB is priced at $0.89, while INSP trades at $42.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas INSP's P/E ratio is 9.70. In terms of profitability, LAB's ROE is -0.21%, compared to INSP's ROE of +0.18%. Regarding short-term risk, LAB is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check INSP's competition here
LAB vs IRMD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, LAB is priced at $0.89, while IRMD trades at $93.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas IRMD's P/E ratio is 51.15. In terms of profitability, LAB's ROE is -0.21%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, LAB is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check IRMD's competition here
LAB vs AVNS Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, LAB is priced at $0.89, while AVNS trades at $24.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas AVNS's P/E ratio is -15.61. In terms of profitability, LAB's ROE is -0.21%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, LAB is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check AVNS's competition here
LAB vs TNDM Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, LAB is priced at $0.89, while TNDM trades at $16.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas TNDM's P/E ratio is -12.12. In terms of profitability, LAB's ROE is -0.21%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, LAB is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check TNDM's competition here
LAB vs SILK Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, LAB is priced at $0.89, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas SILK's P/E ratio is -18.96. In terms of profitability, LAB's ROE is -0.21%, compared to SILK's ROE of -0.35%. Regarding short-term risk, LAB is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SILK's competition here
LAB vs FNA Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, LAB is priced at $0.89, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas FNA's P/E ratio is -19.83. In terms of profitability, LAB's ROE is -0.21%, compared to FNA's ROE of -0.35%. Regarding short-term risk, LAB is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check FNA's competition here
LAB vs CNMD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, CNMD has a market cap of 1B. Regarding current trading prices, LAB is priced at $0.89, while CNMD trades at $34.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas CNMD's P/E ratio is 19.65. In terms of profitability, LAB's ROE is -0.21%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, LAB is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check CNMD's competition here
LAB vs AORT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, AORT has a market cap of 975.7M. Regarding current trading prices, LAB is priced at $0.89, while AORT trades at $20.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas AORT's P/E ratio is 80.40. In terms of profitability, LAB's ROE is -0.21%, compared to AORT's ROE of +0.03%. Regarding short-term risk, LAB is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check AORT's competition here
LAB vs LMRI Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, LMRI has a market cap of 926.2M. Regarding current trading prices, LAB is priced at $0.89, while LMRI trades at $9.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas LMRI's P/E ratio is -24.72. In terms of profitability, LAB's ROE is -0.21%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, LAB is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check LMRI's competition here
LAB vs CSII Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, LAB is priced at $0.89, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas CSII's P/E ratio is -20.83. In terms of profitability, LAB's ROE is -0.21%, compared to CSII's ROE of -0.14%. Regarding short-term risk, LAB is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check CSII's competition here
LAB vs INMD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, INMD has a market cap of 817.9M. Regarding current trading prices, LAB is priced at $0.89, while INMD trades at $13.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas INMD's P/E ratio is 9.96. In terms of profitability, LAB's ROE is -0.21%, compared to INMD's ROE of +0.13%. Regarding short-term risk, LAB is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check INMD's competition here
LAB vs CRY Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, LAB is priced at $0.89, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas CRY's P/E ratio is 425.71. In terms of profitability, LAB's ROE is -0.21%, compared to CRY's ROE of +0.03%. Regarding short-term risk, LAB is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check CRY's competition here
LAB vs CBLL Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, CBLL has a market cap of 700.8M. Regarding current trading prices, LAB is priced at $0.89, while CBLL trades at $18.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas CBLL's P/E ratio is -11.40. In terms of profitability, LAB's ROE is -0.21%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, LAB is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check CBLL's competition here
LAB vs SIBN Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, SIBN has a market cap of 683.9M. Regarding current trading prices, LAB is priced at $0.89, while SIBN trades at $15.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas SIBN's P/E ratio is -39.54. In terms of profitability, LAB's ROE is -0.21%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, LAB is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SIBN's competition here
LAB vs SSII Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, SSII has a market cap of 672.4M. Regarding current trading prices, LAB is priced at $0.89, while SSII trades at $3.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas SSII's P/E ratio is -67.20. In terms of profitability, LAB's ROE is -0.21%, compared to SSII's ROE of -0.23%. Regarding short-term risk, LAB is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check SSII's competition here
LAB vs SRDX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, LAB is priced at $0.89, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas SRDX's P/E ratio is -34.66. In terms of profitability, LAB's ROE is -0.21%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, LAB is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SRDX's competition here
LAB vs TCMD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, TCMD has a market cap of 593.5M. Regarding current trading prices, LAB is priced at $0.89, while TCMD trades at $26.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas TCMD's P/E ratio is 30.24. In terms of profitability, LAB's ROE is -0.21%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, LAB is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check TCMD's competition here
LAB vs APEN Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, LAB is priced at $0.89, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas APEN's P/E ratio is -9.43. In terms of profitability, LAB's ROE is -0.21%, compared to APEN's ROE of -0.85%. Regarding short-term risk, LAB is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check APEN's competition here
LAB vs BVS Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, BVS has a market cap of 576.5M. Regarding current trading prices, LAB is priced at $0.89, while BVS trades at $8.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas BVS's P/E ratio is 20.76. In terms of profitability, LAB's ROE is -0.21%, compared to BVS's ROE of +0.16%. Regarding short-term risk, LAB is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BVS's competition here
LAB vs BWAY Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, BWAY has a market cap of 573.8M. Regarding current trading prices, LAB is priced at $0.89, while BWAY trades at $14.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas BWAY's P/E ratio is 66.50. In terms of profitability, LAB's ROE is -0.21%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, LAB is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check BWAY's competition here
LAB vs ZIMV Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, LAB is priced at $0.89, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, LAB's ROE is -0.21%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, LAB is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ZIMV's competition here
LAB vs NPCE Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, NPCE has a market cap of 533.2M. Regarding current trading prices, LAB is priced at $0.89, while NPCE trades at $15.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas NPCE's P/E ratio is -24.06. In terms of profitability, LAB's ROE is -0.21%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, LAB is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check NPCE's competition here
LAB vs CERS Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, CERS has a market cap of 512.9M. Regarding current trading prices, LAB is priced at $0.89, while CERS trades at $2.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas CERS's P/E ratio is -51.20. In terms of profitability, LAB's ROE is -0.21%, compared to CERS's ROE of -0.15%. Regarding short-term risk, LAB is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check CERS's competition here
LAB vs CTKB Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, CTKB has a market cap of 511.4M. Regarding current trading prices, LAB is priced at $0.89, while CTKB trades at $3.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas CTKB's P/E ratio is -6.83. In terms of profitability, LAB's ROE is -0.21%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, LAB is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check CTKB's competition here
LAB vs VREX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, VREX has a market cap of 464.8M. Regarding current trading prices, LAB is priced at $0.89, while VREX trades at $11.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas VREX's P/E ratio is -5.52. In terms of profitability, LAB's ROE is -0.21%, compared to VREX's ROE of -0.18%. Regarding short-term risk, LAB is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check VREX's competition here
LAB vs KIDS Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, KIDS has a market cap of 457.7M. Regarding current trading prices, LAB is priced at $0.89, while KIDS trades at $17.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas KIDS's P/E ratio is -10.61. In terms of profitability, LAB's ROE is -0.21%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, LAB is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check KIDS's competition here
LAB vs PACB Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, PACB has a market cap of 406.9M. Regarding current trading prices, LAB is priced at $0.89, while PACB trades at $1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas PACB's P/E ratio is -3.20. In terms of profitability, LAB's ROE is -0.21%, compared to PACB's ROE of -4.88%. Regarding short-term risk, LAB is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check PACB's competition here
LAB vs DCTH Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, DCTH has a market cap of 404.6M. Regarding current trading prices, LAB is priced at $0.89, while DCTH trades at $11.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas DCTH's P/E ratio is 1172.00. In terms of profitability, LAB's ROE is -0.21%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, LAB is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check DCTH's competition here
LAB vs CLPT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, CLPT has a market cap of 403.1M. Regarding current trading prices, LAB is priced at $0.89, while CLPT trades at $13.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas CLPT's P/E ratio is -13.44. In terms of profitability, LAB's ROE is -0.21%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, LAB is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check CLPT's competition here
LAB vs VMD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, VMD has a market cap of 400.6M. Regarding current trading prices, LAB is priced at $0.89, while VMD trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas VMD's P/E ratio is 28.24. In terms of profitability, LAB's ROE is -0.21%, compared to VMD's ROE of +0.11%. Regarding short-term risk, LAB is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check VMD's competition here
LAB vs OFIX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, OFIX has a market cap of 376.3M. Regarding current trading prices, LAB is priced at $0.89, while OFIX trades at $9.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas OFIX's P/E ratio is -6.21. In terms of profitability, LAB's ROE is -0.21%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, LAB is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check OFIX's competition here
LAB vs AVR Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, AVR has a market cap of 336.6M. Regarding current trading prices, LAB is priced at $0.89, while AVR trades at $9.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas AVR's P/E ratio is -4.12. In terms of profitability, LAB's ROE is -0.21%, compared to AVR's ROE of -1.24%. Regarding short-term risk, LAB is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check AVR's competition here
LAB vs MASS Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, MASS has a market cap of 312.7M. Regarding current trading prices, LAB is priced at $0.89, while MASS trades at $8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas MASS's P/E ratio is -8.53. In terms of profitability, LAB's ROE is -0.21%, compared to MASS's ROE of -0.26%. Regarding short-term risk, LAB is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check MASS's competition here
LAB vs SMLR Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, LAB is priced at $0.89, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas SMLR's P/E ratio is 3.92. In terms of profitability, LAB's ROE is -0.21%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, LAB is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check SMLR's competition here
LAB vs ELMD Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, ELMD has a market cap of 307.8M. Regarding current trading prices, LAB is priced at $0.89, while ELMD trades at $37.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas ELMD's P/E ratio is 31.77. In terms of profitability, LAB's ROE is -0.21%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, LAB is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ELMD's competition here
LAB vs SENS Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, SENS has a market cap of 299.9M. Regarding current trading prices, LAB is priced at $0.89, while SENS trades at $7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas SENS's P/E ratio is -3.64. In terms of profitability, LAB's ROE is -0.21%, compared to SENS's ROE of -1.30%. Regarding short-term risk, LAB is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check SENS's competition here
LAB vs SGHT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, SGHT has a market cap of 279.1M. Regarding current trading prices, LAB is priced at $0.89, while SGHT trades at $5.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas SGHT's P/E ratio is -7.33. In terms of profitability, LAB's ROE is -0.21%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, LAB is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check SGHT's competition here
LAB vs TMCI Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, TMCI has a market cap of 263.4M. Regarding current trading prices, LAB is priced at $0.89, while TMCI trades at $4.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas TMCI's P/E ratio is -4.23. In terms of profitability, LAB's ROE is -0.21%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, LAB is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check TMCI's competition here
LAB vs PMI Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, PMI has a market cap of 261.9M. Regarding current trading prices, LAB is priced at $0.89, while PMI trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas PMI's P/E ratio is -0.22. In terms of profitability, LAB's ROE is -0.21%, compared to PMI's ROE of +4.99%. Regarding short-term risk, LAB is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check PMI's competition here
LAB vs MGRM Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, LAB is priced at $0.89, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas MGRM's P/E ratio is -11.11. In terms of profitability, LAB's ROE is -0.21%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, LAB is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check MGRM's competition here
LAB vs CATX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, CATX has a market cap of 228.3M. Regarding current trading prices, LAB is priced at $0.89, while CATX trades at $2.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas CATX's P/E ratio is -2.10. In terms of profitability, LAB's ROE is -0.21%, compared to CATX's ROE of -0.42%. Regarding short-term risk, LAB is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check CATX's competition here
LAB vs NVRO Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, LAB is priced at $0.89, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas NVRO's P/E ratio is -1.91. In terms of profitability, LAB's ROE is -0.21%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, LAB is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check NVRO's competition here
LAB vs EYES Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, LAB is priced at $0.89, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas EYES's P/E ratio is N/A. In terms of profitability, LAB's ROE is -0.21%, compared to EYES's ROE of -2.64%. Regarding short-term risk, LAB is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check EYES's competition here
LAB vs PROF Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, PROF has a market cap of 200.5M. Regarding current trading prices, LAB is priced at $0.89, while PROF trades at $6.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas PROF's P/E ratio is -5.34. In terms of profitability, LAB's ROE is -0.21%, compared to PROF's ROE of -0.71%. Regarding short-term risk, LAB is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check PROF's competition here
LAB vs APYX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, APYX has a market cap of 196.4M. Regarding current trading prices, LAB is priced at $0.89, while APYX trades at $4.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas APYX's P/E ratio is -21.32. In terms of profitability, LAB's ROE is -0.21%, compared to APYX's ROE of -0.91%. Regarding short-term risk, LAB is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check APYX's competition here
LAB vs ANIK Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, ANIK has a market cap of 195.9M. Regarding current trading prices, LAB is priced at $0.89, while ANIK trades at $14.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas ANIK's P/E ratio is -18.63. In terms of profitability, LAB's ROE is -0.21%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, LAB is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check ANIK's competition here
LAB vs RXST Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, RXST has a market cap of 195M. Regarding current trading prices, LAB is priced at $0.89, while RXST trades at $4.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas RXST's P/E ratio is -4.44. In terms of profitability, LAB's ROE is -0.21%, compared to RXST's ROE of -0.17%. Regarding short-term risk, LAB is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check RXST's competition here
LAB vs BSGM Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, LAB is priced at $0.89, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas BSGM's P/E ratio is -5.81. In terms of profitability, LAB's ROE is -0.21%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, LAB is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check BSGM's competition here
LAB vs MDGS Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, LAB is priced at $0.89, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas MDGS's P/E ratio is -0.27. In terms of profitability, LAB's ROE is -0.21%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, LAB is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check MDGS's competition here
LAB vs EDAP Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, LAB is priced at $0.89, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas EDAP's P/E ratio is -5.80. In terms of profitability, LAB's ROE is -0.21%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, LAB is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check EDAP's competition here
LAB vs FOCL Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, FOCL has a market cap of 178M. Regarding current trading prices, LAB is priced at $0.89, while FOCL trades at $4.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas FOCL's P/E ratio is -5.79. In terms of profitability, LAB's ROE is -0.21%, compared to FOCL's ROE of -1.37%. Regarding short-term risk, LAB is more volatile compared to FOCL. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check FOCL's competition here
LAB vs INGN Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, INGN has a market cap of 173.3M. Regarding current trading prices, LAB is priced at $0.89, while INGN trades at $6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas INGN's P/E ratio is -7.03. In terms of profitability, LAB's ROE is -0.21%, compared to INGN's ROE of -0.13%. Regarding short-term risk, LAB is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check INGN's competition here
LAB vs QIPT Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, LAB is priced at $0.89, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas QIPT's P/E ratio is -15.87. In terms of profitability, LAB's ROE is -0.21%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, LAB is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check QIPT's competition here
LAB vs QTRX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, QTRX has a market cap of 146M. Regarding current trading prices, LAB is priced at $0.89, while QTRX trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas QTRX's P/E ratio is -1.32. In terms of profitability, LAB's ROE is -0.21%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, LAB is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check QTRX's competition here
LAB vs TLSI Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, TLSI has a market cap of 142.9M. Regarding current trading prices, LAB is priced at $0.89, while TLSI trades at $3.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas TLSI's P/E ratio is -2.55. In terms of profitability, LAB's ROE is -0.21%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, LAB is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check TLSI's competition here
LAB vs CVRX Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, CVRX has a market cap of 133.5M. Regarding current trading prices, LAB is priced at $0.89, while CVRX trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas CVRX's P/E ratio is -2.50. In terms of profitability, LAB's ROE is -0.21%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, LAB is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for LAB.Check CVRX's competition here
LAB vs SNWV Comparison June 2026
LAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 346.5M. In comparison, SNWV has a market cap of 128.2M. Regarding current trading prices, LAB is priced at $0.89, while SNWV trades at $14.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -6.83, whereas SNWV's P/E ratio is 15.53. In terms of profitability, LAB's ROE is -0.21%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, LAB is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for LAB.Check SNWV's competition here